Recent Updates
Recently added Catalysts

Influenza Vaccine GSK1247446A

Phase 2

Influenza | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Jun 26, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials2
Total Enrollment921
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00545025Revaccination With Influenza Vaccine GSK1247446APHASE2 COMPLETED 243Oct 15, 2007Dec 12, 2007Jun 26, 20191 Belgium
NCT00385840Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine CandidatePHASE2 COMPLETED 678Oct 20, 2006Feb 5, 2007Jun 8, 20184 Norway
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms
During a 7-day (Days 0-6) follow-up period after re-vaccination

Assessed solicited local symptoms were ecchymosis, pain, redness and swelling at injection site. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal everyday activity. Grade 3 redness/swelling/ecchymosis = redness/swelling/ecchymosis spreading beyond 50 millimeters (mm) of the injection site. All solicited local symptoms assessed were considered by the investigator as related to study vaccination.

Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.
During a 7-day (Days 0-6) follow-up after re-vaccination

Assessed solicited general symptoms were arthralgia, fatigue, fever \[oral temperature equal to or above ≥ 37.5 degrees Celsius (°C)\], headache, myalgia, nausea and shivering. Any = incidence of a particular symptom regardless of grade intensity or relationship with the study vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0°C. Related = symptom considered by the investigator to have a causal relationship to study vaccination.

Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
During a 30-day (Days 0-29) follow-up period after re-vaccination

Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal activity. Related = unsolicited AE assessed by the investigator as causally related to the study vaccination.

Number of Subjects With Any and Related Serious Adverse Events (SAEs)
During the entire study period (Days 0-30)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Related = SAE assessed by the investigator as causally related to the study vaccination.

Number of Subjects With Any and Grade 3 Solicited Local Symptoms.
During the 7-day (Days 0-6) post-vaccination period

Assessed solicited local symptoms were ecchymosis, pain, redness and swelling. Any = Incidence of a particular solicited local symptom regardless of intensity grade. Grade 3 pain = Pain that prevented normal everyday activity. Grade 3 redness/swelling/ecchymosis = Redness/swelling/ecchymosis above 50 millimeters (mm).

Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).
During the 30-day (Days 0-29) post vaccination period

Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = Any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = Unsolicited AE that prevented normal activity. Related = Unsolicited AE assessed by the investigator as causally related to the vaccination.

Number of Subjects With Any and Related Serious Adverse Events (SAEs).
During the entire study period (from Day 0 to Day 29)

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any SAE = Occurrence of any SAE regardless of intensity grade or relation to vaccination Related = SAE considered by the investigator to have a causal relationship to study vaccination.

Secondary Endpoints
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.
At Days 0 and 21
Number of Seroconverted Subjects Against 3 Strains of Influenza Disease.
At Day 21
Number of Seroprotected Subjects Against 3 Strains of Influenza Disease.
At Day 0 and 21
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
GSK1247446A GroupEXPERIMENTALSubjects aged between 18 and 60 years, having previously received one dose of the AS03-adjuvanted GSK1247446A vaccine in the primary study NCT00374842, received a single dose of GSK1247446A vaccine adjuvanted with a half dose of AS03 adjuvant at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Subjects in this group originated from either the GSK1247446A Formulation 1 or GSK1247446A Formulation 2 groups in study NCT00374862.
Fluarix GroupACTIVE_COMPARATORSubjects aged between 18 and 60 years, having previously received one dose of Fluarix™ vaccine during the primary study NCT00374842, received one dose of Fluarix™ vaccine at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltiod region of the non-dominant arm. Subjects in this group originated from the Fluarix Group in study NCT00374862.
Interventions
NameTypeDescription
Influenza Vaccine GSK1247446ABIOLOGICALSingle dose, Intramuscular injection
Fluarix™BIOLOGICALSingle dose, Intramuscular injection
FluarixTMBIOLOGICALSingle dose, intramuscular injection
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 60 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * A male or female aged 18-60 years old at the time of vaccination, who previously participated in 108656 clinical trial. * Subjects who the investigator believes that they can and will comply with the requirements of the protocol. * Written informed consent obtained from the su...

Countries:BelgiumNorway
Unlock Eligibility Criteria